CLAIMS

1. Use of a composition comprising a hyaluronidase in the manufacture of a medicament for reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye in an individual in need thereof, wherein the hyaluronidase is to be administered to a suprachoroidal space of the eye in a concentration of at least 3,000 IU/mL.

2. Use of a composition comprising a hyaluronidase in the manufacture of a medicament for reducing or inhibiting a vascular occlusion in an eye of an individual in need thereof, wherein the hyaluronidase is to be administered to a suprachoroidal space of the eye in a concentration of at least 3,000 IU/mL.

3. Use of a composition comprising a hyaluronidase in the manufacture of a medicament for reducing or inhibiting a hyaluronic acid-induced loss of vision in an individual in need thereof, wherein the hyaluronidase is to be administered to a suprachoroidal space of the eye in a concentration of at least 3,000 IU/mL.

4. The use according to any one of claims 1-3, wherein the composition is to be administered using a delivery system.

5. The use according to claim 4, wherein the delivery system comprises a needle and syringe, an ADG needle, or a microinjector.

6. The use according to claim 5, wherein the microinjector is a suprachoroidal microinjector.

7. The use according to any one of claims 1-6, wherein the composition comprises the hyaluronidase in a concentration of at least 10,000 IU/mL.

8. The use according to any one of claims 1-7, wherein the composition comprises the hyaluronidase in a concentration of at least 20,000 IU/mL.

9. The use according to any one of claims 1-8, wherein the composition is to be administered as a single dose or in multiple doses.

10. A delivery system comprising a composition including a hyaluronidase suitable for use in reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye of an individual in need thereof, wherein the hyaluronidase is to be administered to a suprachoroidal space of the eye in a concentration of at least 3,000 IU/mL.

11. A delivery system comprising a composition comprising a hyaluronidase suitable for use in reducing or inhibiting a vascular occlusion in an eye of an individual in need thereof, wherein the hyaluronidase is to be administered to a suprachoroidal space of the eye in a concentration of at least 3,000 IU/mL.

12. A delivery system comprising a composition comprising a hyaluronidase suitable for use in reducing or inhibiting a hyaluronic acid-induced loss of vision in an individual in need thereof, wherein the hyaluronidase is to be administered to a suprachoroidal space of the eye in a concentration of at least 3,000 IU/mL.

13. The delivery system according to any one of claims 1-12, wherein the delivery system comprises a needle and syringe, an ADG needle, or a microinjector.

14. The delivery system according to claim 13, wherein the microinjector is a suprachoroidal microinjector.

15. The delivery system according to any one of claims 10-14, wherein the composition comprises the hyaluronidase in a concentration of at least 10,000 IU/mL.

16. The delivery system according to any one of claims 10-15, wherein the composition is to be administered as a single dose or in multiple doses.

17. A kit comprising one or more suprachoroidal microinjectors, each suprachoroidal microinjector including a pharmaceutical composition including a hyaluronidase, wherein the hyaluronidase is in a volume of 5 µl to 500 µl and at a concentration of at least 3,000 IU/mL.